126 related articles for article (PubMed ID: 9135501)
1. Combination of the new minor groove alkylator tallimustine and melphalan.
Tagliabue G; Filippini C; Ubezio P; D'Incalci M
Eur J Cancer; 1997 Feb; 33(2):284-7. PubMed ID: 9135501
[TBL] [Abstract][Full Text] [Related]
2. Comparison of cell-cycle phase perturbations induced by the DNA-minor-groove alkylator tallimustine and by melphalan in the SW626 cell line.
Erba E; Mascellani E; Pifferi A; D'Incalci M
Int J Cancer; 1995 Jul; 62(2):170-5. PubMed ID: 7622292
[TBL] [Abstract][Full Text] [Related]
3. Cytotoxic and antitumor activity of MEN 10710, a novel alkylating derivative of distamycin.
Bigioni M; Salvatore C; Palma C; Manzini S; Animati F; Lombardi P; Pratesi G; Supino R; Zunino F
Anticancer Drugs; 1997 Oct; 8(9):845-52. PubMed ID: 9402311
[TBL] [Abstract][Full Text] [Related]
4. Sequence-specific DNA alkylation of novel tallimustine derivatives.
Marchini S; Cozzi P; Beria I; Geroni C; Capolongo L; D'Incalci M; Broggini M
Anticancer Drug Des; 1998 Apr; 13(3):193-205. PubMed ID: 9595033
[TBL] [Abstract][Full Text] [Related]
5. Alpha-bromoacryloyl derivative of distamycin A (PNU 151807): a new non-covalent minor groove DNA binder with antineoplastic activity.
Marchini S; Cirò M; Gallinari F; Geroni C; Cozzi P; D'Incalci M; Broggini M
Br J Cancer; 1999 Jun; 80(7):991-7. PubMed ID: 10362106
[TBL] [Abstract][Full Text] [Related]
6. The effects of a benzoic acid mustard derivative of distamycin A (FCE 24517) and related minor groove-binding distamycin analogues on the activity of major groove-binding alkylating agents.
Coley HM; Mongelli N; D'Incalci M
Biochem Pharmacol; 1993 Feb; 45(3):619-26. PubMed ID: 8442762
[TBL] [Abstract][Full Text] [Related]
7. Tallimustine, an effective antileukemic agent in a severe combined immunodeficient mouse model of adult myelogenous leukemia, induces remissions in a phase I study.
Beran M; Jeha S; O'Brien S; Estey E; Vitek L; Zurlo MG; Rios MB; Keating M; Kantarjian H
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2377-84. PubMed ID: 9815637
[TBL] [Abstract][Full Text] [Related]
8. PNU 157977: a new potent antitumour agent exhibiting low in vivo toxicity in mice injected with L1210 leukaemia cells.
Baraldi PG; Balboni G; Romagnoli R; Spalluto G; Cozzi P; Geroni C; Mongelli N; Rutigliano C; Bianchi N; Gambari R
Anticancer Drug Des; 1999 Feb; 14(1):71-6. PubMed ID: 10363029
[TBL] [Abstract][Full Text] [Related]
9. DNA sequence-recognizing properties of minor groove alkylating agents. Effects of the replacement of N-methylpyrrole by an N-methylimidazole on tallimustine and its own homologue.
Baraldi PG; Romagnoli R; Spalluto G; Cozzi P; Mongelli N; Bianchi N; Gambari R
Arzneimittelforschung; 2000 Mar; 50(3):309-15. PubMed ID: 10758785
[TBL] [Abstract][Full Text] [Related]
10. Hematopoietic toxicity and cell cycle perturbations induced by new DNA minor groove-alkylating agents.
Filippini C; Bisiach M; Tagliabue G; D'Incalci M; Ubezio P
Int J Cancer; 1997 Sep; 72(5):801-9. PubMed ID: 9311597
[TBL] [Abstract][Full Text] [Related]
11. Phase I study of the novel distamycin derivative tallimustine (FCE 24517).
Sessa C; Pagani O; Zurlo MG; de Jong J; Hofmann C; Lassus M; Marrari P; Strolin Benedetti M; Cavalli F
Ann Oncol; 1994 Dec; 5(10):901-7. PubMed ID: 7696161
[TBL] [Abstract][Full Text] [Related]
12. Biological profile of FCE 24517, a novel benzoyl mustard analogue of distamycin A.
Pezzoni G; Grandi M; Biasoli G; Capolongo L; Ballinari D; Giuliani FC; Barbieri B; Pastori A; Pesenti E; Mongelli N
Br J Cancer; 1991 Dec; 64(6):1047-50. PubMed ID: 1764367
[TBL] [Abstract][Full Text] [Related]
13. A new class of cytotoxic DNA minor groove binders: alpha-halogenoacrylic derivatives of pyrrolecarbamoyl oligomers.
Cozzi P
Farmaco; 2001; 56(1-2):57-65. PubMed ID: 11347968
[TBL] [Abstract][Full Text] [Related]
14. Combinatorial identification of a novel consensus sequence for the covalent DNA-binding polyamide tallimustine.
Sunavala-Dossabhoy G; Van Dyke MW
Biochemistry; 2005 Feb; 44(7):2510-22. PubMed ID: 15709763
[TBL] [Abstract][Full Text] [Related]
15. Development of distamycin-related DNA binding anticancer drugs.
Marchini S; Broggini M; Sessa C; D'Incalci M
Expert Opin Investig Drugs; 2001 Sep; 10(9):1703-14. PubMed ID: 11772279
[TBL] [Abstract][Full Text] [Related]
16. A phase I and pharmacokinetic study of tallimustine [PNU 152241 (FCE 24517)] in patients with advanced cancer.
Weiss GR; Poggesi I; Rocchetti M; DeMaria D; Mooneyham T; Reilly D; Vitek LV; Whaley F; Patricia E; Von Hoff DD; O'Dwyer P
Clin Cancer Res; 1998 Jan; 4(1):53-9. PubMed ID: 9516952
[TBL] [Abstract][Full Text] [Related]
17. DNA sequence-specific adenine alkylation by the novel antitumor drug tallimustine (FCE 24517), a benzoyl nitrogen mustard derivative of distamycin.
Broggini M; Coley HM; Mongelli N; Pesenti E; Wyatt MD; Hartley JA; D'Incalci M
Nucleic Acids Res; 1995 Jan; 23(1):81-7. PubMed ID: 7870593
[TBL] [Abstract][Full Text] [Related]
18. Establishment of L1210 leukemia cells resistant to the distamycin-A derivative (FCE 24517): characterization and cross-resistance studies.
Geroni C; Pesenti E; Tagliabue G; Ballinari D; Mongelli N; Broggini M; Erba E; D'Incalci M; Spreafico F; Grandi M
Int J Cancer; 1993 Jan; 53(2):308-14. PubMed ID: 8425770
[TBL] [Abstract][Full Text] [Related]
19. Cytotoxics derived from distamycin A and congeners.
Cozzi P; Mongelli N
Curr Pharm Des; 1998 Jun; 4(3):181-201. PubMed ID: 10197039
[TBL] [Abstract][Full Text] [Related]
20. Selective DNA interaction of the novel distamycin derivative FCE 24517.
Broggini M; Erba E; Ponti M; Ballinari D; Geroni C; Spreafico F; D'Incalci M
Cancer Res; 1991 Jan; 51(1):199-204. PubMed ID: 1859575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
